PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

274

Participants

Timeline

Start Date

February 8, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Prostate Cancer
Interventions
DRUG

Piflufolastat F 18 Intravenous Solution [PYLARIFY]

Participants will receive a single dose of 333 MBq (9 mCi) \[296 MBq-370 MBq (8 mCi - 10 mCi)\] PYLARIFY injection followed by a single whole-body PET/CT or PET/MRI scan acquired at 1 to 2 hours post-dosing

Trial Locations (14)

21205

Johns Hopkins University, Baltimore

30322

Emory University, Atlanta

35249

University of Alabama at Birmingham, Birmingham

44195

Cleveland Clinic, Cleveland

48201

Karmanos Cancer Institute Wayne State University, Detroit

49503

BAMF Health, Grand Rapids

52242

University of Iowa Health Care, Iowa City

63110

Washington University School of Medicine, St Louis

84112

Huntsman Cancer Institute University of Utah, Salt Lake City

90048

Tower Urology, Los Angeles

92618

Hoag Cancer Center, Irvine

94158

University of California San Francisco, San Francisco

97239

Oregon Health & Science University, Portland

02114

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
lead

Lantheus Medical Imaging

INDUSTRY